Rendering courtesy of The RMR Group Unison LifeScience

Sono­ma Bio to ce­ment its roots in Seat­tle with a new wa­ter­front man­u­fac­tur­ing and R&D site

A year af­ter Jeff Blue­stone’s Sono­ma Bio­ther­a­peu­tics net­ted $265 mil­lion in a huge Se­ries B, the biotech is now look­ing to es­tab­lish it­self in the man­u­fac­tur­ing ecosys­tem of the Pa­cif­ic North­west.

Sono­ma has en­tered in­to a lease agree­ment to de­vel­op an 83,000-square-foot man­u­fac­tur­ing and R&D cen­ter in Seat­tle, the com­pa­ny said Wednes­day. The com­pa­ny’s gene mod­i­fied Treg ther­a­pies, born out of the R&D lab in South San Fran­cis­co, will be made at the site.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.